Home > Insider Trading > Filing (0000899243-20-027297)

Filing Details

Accession Number:: 0000899243-20-027297
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-10-05 17:00:10
Reporting Period:: 2020-07-16

Accepted Time:: 2020-10-05 17:00:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1664106	Logicbio Therapeutics Inc.	LOGC	Biological Products, (No Disgnostic Substances) (2836)	471514975

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1700449	Plc Bioscience Arix	20 Berkeley Square Mayfair, London X0 W1J6EQ		No	No	Yes	No
1756884	Ltd Holdings Bioscience Arix	20 Berkley Square Mayfair, London X0 W1J6EQ		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-07-16	16,332	$8.56	2,962,691	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-07-17	31,101	$9.24	2,931,590	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-07-20	36,983	$9.25	2,894,607	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-07-22	22,651	$9.00	2,871,956	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-07-29	2,709	$8.78	2,869,247	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-08-12	1,335	$8.79	2,867,912	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-08-13	159	$8.75	2,867,753	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-09-24	38,514	$7.63	2,829,239	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-09-25	174,219	$7.08	2,655,020	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-09-28	273,584	$7.54	2,381,436	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.685 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer.
These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.415 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.05 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.91 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.35 to $7.70 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.00 to $8.15 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.75 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.